跳至主要内容
临床试验/NCT06488027
NCT06488027已完成不适用

DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS

AB Biotek1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年5月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
1
主要终点
number of patients with insomnia symptoms and DAO deficiency

研究概览

简要总结

Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can lead to symptoms in the nervous system, among others. In this study we wanted to study the prevalence of DAO deficiency in pacients with insomnia symptoms.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Older than 18 years old
  • With one or more symptoms of insomnia
  • Explicit acceptance to participate to the study through informed consent

排除标准

  • Insomnia symptoms that could be justified by the existance of another sleep pathology (e.g., narcolepsy)

结局指标

主要结局

number of patients with insomnia symptoms and DAO deficiency

时间窗: at the time of enrollment

number (absolute and percentage) of patients with insomnia symptoms and DAO deficiency

次要结局

未报告次要终点

研究者

发起方
AB Biotek
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验